[
    [
        {
            "time": "2018-01-02",
            "original_text": "AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug",
            "features": {
                "keywords": [
                    "FDA",
                    "label expansion",
                    "HCV drug"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "FTC requests AbbVie, Allergan for more information on $63 billion deal",
            "features": {
                "keywords": [
                    "FTC",
                    "information request",
                    "deal"
                ],
                "sentiment_score": -0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "FTC requests AbbVie, Allergan for more information on $63 billion deal",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "Allergan and AbbVie Receive Second Request from Federal Trade Commission on Pending Transaction",
            "features": {
                "keywords": [
                    "FTC",
                    "second request",
                    "pending transaction"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Allergan and AbbVie Receive Second Request from Federal Trade Commission on Pending Transaction",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "This is Why AbbVie (ABBV) is a Great Dividend Stock",
            "features": {
                "keywords": [
                    "dividend stock"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "This is Why AbbVie (ABBV) is a Great Dividend Stock",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-06",
            "original_text": "AbbVie Receives FDA Approval of MAVYRET速 (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Na誰ve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes",
            "features": {
                "keywords": [
                    "FDA approval",
                    "MAVYRET",
                    "treatment duration"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie Receives FDA Approval of MAVYRET速 (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Na誰ve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]